Adenocarcinoma/therapy; Antineoplastic Combined Chemotherapy Protocols/therapeutic use; Carcinoma, Squamous Cell/therapy; Esophageal Neoplasms/therapy; Esophagectomy; Patient Selection; Adenocarcinoma/drug therapy; Adenocarcinoma/radiotherapy; Adenocarcinoma/secondary; Adenocarcinoma/surgery; Antineoplastic Combined Chemotherapy Protocols/adverse effects; Carcinoma, Squamous Cell/drug therapy; Carcinoma, Squamous Cell/mortality; Carcinoma, Squamous Cell/radiotherapy; Carcinoma, Squamous Cell/secondary; Carcinoma, Squamous Cell/surgery; Chemotherapy, Adjuvant; Disease-Free Survival; Esophageal Neoplasms/drug therapy; Esophageal Neoplasms/mortality; Esophageal Neoplasms/radiotherapy; Esophageal Neoplasms/secondary; Esophageal Neoplasms/surgery; Esophagectomy/adverse effects; Esophagectomy/mortality; Humans; Lymph Node Excision; Lymphatic Metastasis; Neoadjuvant Therapy; Neoplasm Invasiveness; Neoplasm Staging; Neoplasm, Residual; Radiotherapy, Adjuvant; Time Factors; Treatment Outcome